Alzheimer's Drug Lecanemab Shows Promising Results In Slowing Disease
Alzheimer’s Drug Lecanemab Shows Promising Results In Slowing Disease New research published yesterday inThe New England Journal of Medicinesuggests that lecanemab, an antibody to the substance that accumulates in the brain leading to Alzheimer’s Disease, may have success in treating — or at least slowing — the ruthless disease’s progression. The study examined a group of early-stage Alzheimer’s patients ranging from 50 to 90 years old: half received lecanemab, and half received a placebo....